ReviewCells2021
Perspectives and Issues in the Assessment of
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Intestinal SMARCA4-deficient undifferentiated carcinoma: a case series and systematic review of the literature.World journal of surgical oncology · 2026Pooled it
- A DoE-Dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: Application to the PROTAC ACBI2.International journal of pharmaceutics: X · 2026Article
- Therapeutic advances with KRASCancer gene therapy · 2026Review
- Clinicopathological and Genomic Analysis ofCancer management and research · 2026Article
- Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports.Discover oncology · 2025Article
- ThoracicRadiology case reports · 2025Article
- [Molecular pathology in non-small-cell lung cancer: current and emerging biomarkers].Pathologie (Heidelberg, Germany) · 2025Review
- Gastric SMARCA4-deficient undifferentiated tumors: clinicopathological analysis of two cases in a single center.Diagnostic pathology · 2025Article
- Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics.Clinical & experimental metastasis · 2025Article
- SMARCA4 deficiency in small cell lung cancer: A case report and narrative review of the literature.Biomolecules & biomedicine · 2025Review
- Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker.Frontiers in immunology · 2025Article
- Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer.Frontiers in oncology · 2025Article
- Fine-needle aspiration and effusion cytology of thoracic SMARCA4-deficient undifferentiated tumor and SMARCA4-deficient non-small cell lung carcinoma: A multi-institutional experience with 27 patients.Cancer cytopathology · 2025Article
- SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response.FEBS open bio · 2024Article
- SMARCA4 deficient undifferentiated tumours: An emerging entity in lung cancer.Lung India : official organ of Indian Chest Society · 2024Article
- A Critical Review of the Impact ofJournal of personalized medicine · 2024Review
- SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features.Journal of thoracic disease · 2024Article
- SMARCA4-deficient tumors in the adrenal gland and small intestines: A rare case report.Radiology case reports · 2024Article
- Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.Virchows Archiv : an international journal of pathology · 2024Review
- Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancers are ranked third among the cancer incidence in France in the year 2020, with adenocarcinomas being the commonest sub-type out of ~85% of non-small cell lung carcinomas. The constant evolution of molecular genotyping, which is used for the management of lung adenocarcinomas, has led to the current focus on tumor suppressor genes, specifically the loss of function mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.